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Abstract Diabetes is one of the main economic burdens in
health care, which threatens to worsen dramatically if preva-
lence forecasts are correct.Whatmakes diabetes harmful is the
multi-organ distribution of its microvascular and
macrovascular complications. Regenerative medicine with
cellular therapy could be the dam against life-threatening or
life-altering complications. Bone marrow-derived stem cells
are putative candidates to achieve this goal. Unfortunately, the
bone marrow itself is affected by diabetes, as it can develop a
microangiopathy and neuropathy similar to other body tissues.
Neuropathy leads to impaired stem cell mobilization from
marrow, the so-called mobilopathy. Here, we review the role
of bone marrow-derived stem cells in diabetes: how they are
affected by compromised bone marrow integrity, how they
contribute to other diabetic complications, and how they can
be used as a treatment for these. Eventually, we suggest new
tactics to optimize stem cell therapy.
Keywords Diabetes . Diabetic complications . Bone
marrow . Stem cells . Microangiopathy . Cell regenerative
therapy
Introduction
Diabetes mellitus (DM) is a family of metabolic disorders
characterized by high blood glucose levels. Worldwide, there
are about 387 million people affected by DM, with a preva-
lence in North America of 11.4 % (39 million) and in Europe
of 7.9 % (52 million) (http://www.idf.org/sites/default/files/
DA-regional-factsheets-2014_FINAL.pdf). Estimation for
2035 foresees 592 million patients with diabetes on the
planet. It is not surprising that DM is one of the heaviest
economic health burdens, with an annual global cost of 548
million USD raising to 627 million in 2035 (http://www.idf.
org/sites/default/files/DA-regional-factsheets-2014_FINAL.
pdf).
There are several types of DM. Type 1 diabetes
(T1DM) is an autoimmune disease characterized by β-
cell destruction in the pancreatic islets resulting in the
complete loss of insulin secretion. Type 2 diabetes
(T2DM), the prevalent form of DM, is a multifactorial
disease characterized by insulin resistance. Gestational di-
abetes (GDM) occurs in pregnant women without previous
history of DM. Chronic hyperglycemia causes systemic
complications, with cardiovascular complications being
particularly frequent and worrisome [1]. Diabetic
macrovascular disease manifests as coronary artery disease
(CAD), myocardial infarction (MI), peripheral artery dis-
ease (PAD), and stroke. Microvascular disease results from
damage to the small vessels and can aggravate the out-
come of patients with occlusive macrovascular disease.
Compared to hospital costs of people without complica-
tions, hospital costs of those with microvascular complica-
tions are doubled, those of people with macrovascular
complications are tripled, and those of people with both
micro- and macrovascular complications are six times as
great. Lifestyle interventions, such as changes in diet and
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exercise, and medications are essential in reducing the risk
for development of complications. Thanks to improved
management, the prevalence of diabetic complications is
constantly decreasing, but these improved clinical out-
comes came with a cost of £708 million per year in the
UK, corresponding to 7 % of the UK health-care prescrib-
ing budget [2]. Nevertheless, once cardiovascular compli-
cations occur, these are more difficult to treat in patients
with DM as compared with patients without DM. This
difference has been explained with the fact that healing
and regenerative mechanisms are remarkably altered in
patients with DM.
The current care of cardiovascular complications com-
prises pharmacotherapy and revascularization. However,
medical treatment can be ineffective as in the case of refrac-
tory angina, which is prevalent in patients with DM.
Additionally, in many patients with DM, revascularization
cannot be applied due to multiple and distal occlusions, or it
fails because of restenosis. But the most important limitation
of medical and interventional treatments is that, even when
successful, they do not replace cells irreversibly damaged by
ischemia. Therefore, intense research is focused on regenera-
tive medicine as a novel option for the treatment of cardiovas-
cular complications. This approach consists of augmenting
endogenous mechanisms of repair by supplements of regen-
erative cells, for instance through transplantation of stem cells/
progenitor cells into the infarcted myocardium. Alternatively,
cytokines and growth factors could be delivered to boost the
liberation of progenitor cells from the bone marrow (BM) or
the expansion of resident progenitor cells in the heart and
other ischemic tissues. To date, a few thousand individuals
worldwide have received stem cells—mainly BM cells—in
cardiovascular clinical trials [3].
In this review, we provide a concise report of the latest
findings about cell therapy for treatment of diabetic complica-
tions, with particular focus on approaches based on BM-
derived cells. We also discuss the pros and cons of BM cell
therapy, especially in light of new discoveries that common
complications of DM, namely microangiopathy and neuropa-
thy, affect also the BM and may jeopardize stem cell mobili-
zation following an ischemic event or stimulation by cyto-
kines. Finally, we propose some possible solutions to improve
current cell therapy approaches.
Bone Marrow-Derived Stem Cells and Their Niches
BM is the only reservoir of human pluripotent stem cells
(HPSCs) in the adult human body, providing a specific micro-
environment to support stem cell maintenance and/or expan-
sion. Here, we provide a brief overview of the different cell
populations of interest and their organization in the BM niche.
Hematopoietic Stem Cells
Hematopoietic stem cells (HSCs) constitute a very heteroge-
neous population, which can give rise to any blood cell. They
are defined as proper stem cells because of their self-renewal
capacity and multipotency [4]. BM transplantation assays in
animal models helped to establish a possible hierarchical
structure. Accordingly, based on repopulating capacity upon
transplantation into irradiated animals, two different popula-
tions have been identified and defined as short-term HSCs
(ST-HSC) and long-term HSCs (LT-HSCs) [5]. In humans,
the surface marker CD34, a member of a family of single-
pass transmembrane glycoproteins, is considered the main
defining marker for HSCs and the marker of choice to select
populations for clinical cell therapy trials. Depleting CD34+
cells for Lin antigen enables their enrichment into a more
primitive population with hematopoietic function. Further en-
richment could be achieved by selecting the latter population
for Thy1, a primitive stem cell marker, and depleting for
CD38 and CD45RA markers (multipotent progenitors), with
additional positivity for CD49f defining proper LT-HSCs [6].
In the mouse, LT-HSCs are identified as CD34−/c-Kit+/Sca-
1+/Lineage− (CD34−/KSL) cells. However, CD34−/KSL
cells represent a heterogeneous population containing sub-
fractions with diverse regenerative capacity. Further character-
ization by use of the signaling lymphocyte activation mole-
cule (SLAM) markers CD48 and CD150 allows the identifi-
cation of a fraction of CD34−/KSL cells endowed with high
self-renewal potential and repopulating capacity [4]. The sem-
inal concept of BM HSCs directly participating in de novo
post-natal vasculogenesis, proposed some years ago by
Asahara et al. [7], has been revised in light of the novel indi-
cation that paracrine mechanisms, rather than the conversion
of one cell type to another, control the interrelation between
hematopoietic and vascular cells [8].
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are a heterogeneous
multipotent stromal cell population well represented in BM
as well as in several other adult tissues. They are defined as
plastic-adherent, fibroblast-like cells endowed with high pro-
liferative activity and capacity to differentiate into a variety of
cell types, including osteoblasts (bone cells), chondrocytes
(cartilage cells), myocytes (muscle cells), and adipocytes (fat
cells) [9]. They typically express the mesenchymal markers
CD44, CD90, CD49, CD54, CD105, and CD73, but are neg-
ative for both hematopoietic markers, such as CD45, CD14,
and CD11b, and endothelial markers, such as CD144, von
Willebrand factor (vWf), and VCAM-1 [9]. MSCs have been
shown to possess special plasticity. In fact, under appropriate
experimental conditions, they can also differentiate into non-
mesenchymal cells—for instance, neural cells and endothelial
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cells [10]. In addition, MSCs exert pro-angiogenic and immu-
nomodulatory activities, through the secretion of different
cytokines/growth factors [11], altogether making MSCs a
popular choice for regenerative medicine applications.
Endothelial Progenitor Cells
Endothelial progenitor cells (EPCs) are angiogenic cells char-
acterized for the first time by Ishikawa and Asahara in 1997
[12]. Since their discovery, many definitions have been pro-
posed, creating a maelstrom of overlapping nomenclatures.
Scientific consensus agreed on defining EPCs as a subset of
myeloid/monocyte cells which can acquire endothelial
markers, such as CD31, KDR, or vWf, together with lectin-
binding ability in in vitro culture conditions [13]. They have to
be considered a different population from endothelial colony-
forming cells (ECFCs), a non-marrow-derived population,
and more resembling endothelial cells likely originated from
vessel-associated progenitor cells [14]. EPCs exert their pro-
angiogenic potential in a paracrine fashion rather than differ-
entiating in vascular cytotype [15]. EPCs have been extensive-
ly studied in animal models and clinical trials thanks to their
supportive role in angiogenesis.
Localization of Stem Cells in the BM Niche
The BM is found within the cavities of long bones. The
trabecular bone structure endowed with spare adipocytes
provides a supportive meshwork for niches. Two differ-
ent types of niches have been identified so far. The
osteoblastic niche localized near the endosteal part of
the bone provides a shelter for most primitive HSCs.
A mixture of different cells contributes to the mainte-
nance of HSC homeostasis. In particular, osteoblasts and
macrophages play a pivotal role in regulating the end-
osteal niche milieu. Osteoblasts regulate the niche
through Wnt signaling, and their depletion leads to
niche pauperization [16]. A particular subset of macro-
phages, expressing CD169, could regulate the abun-
dance of osteoblasts and also regulate the retention-
mobilization of HSCs [17]. The vascular niche is orga-
nized around sinusoidal vessels and harbors more com-
mitted HSCs. In this niche, endothelial cells and
perivascular cells are the main regulators. Endothelial
cells mediate maintenance of HSC homeostasis through
production of Akt-related angiocrine factors, such as
angiopoietin-1, delta-like 1, insulin-like growth factor-
binding protein 2, and epidermal growth factor [18].
Perivascular cells positive for CD146, platelet growth
factor receptor α, and nestin could be recognized
around the sinusoids. They express two master regula-
tors of HSC homeostasis: the chemokine (C-X-C motif)
ligand 12 (CXCL-12) and stem cell factor (SCF) [19]. It
has also been observed that perivascular cells exert their
effects through cell-to-cell contacts via the Notch signal-
ing pathway [19]. This spatial organization creates a
gradient, in which HSCs could progress from the most
primitive self-renewal state to lineage commitment,
ready for egression into the bloodstream. Additionally,
reactive oxygen species (ROS) distribute according to
the BM perfusion gradient, with higher levels in the
vascular niche and lower levels in the endosteal niche
[20•]. This gradient contributes in maintaining the bal-
ance between stem cell self-renewal and differentiation
across the niches [20•].
The Upside: Evidence for BM-Derived Stem Cells
Improving Diabetic Complications
Diabetic Retinopathy
Diabetic retinopathy (DR) is the major cause of vision impair-
ment in working-age adults in western countries [21]. The
main accepted mechanism in DR development is related to
the loss of pericytes. They provide a nourishing, anti-inflam-
matory, and stabilizing microenvironment for human retinal
endothelial cells (HREC). In the early stage, DM impairs
pericyte self-renewal and endothelial cell survival, resulting
in a hypoxic retinal microenvironment [22]. This triggers the
translocation of hypoxia-inducible factor-1 alpha (HIF-1a),
which in turn leads to the upregulated expression of vascular
endothelial growth factor A (VEGF-A). Persistent VEGF-A
production stimulates retinal angiogenesis, fibroblast scar for-
mation, and vascular leakage, resulting in proliferative diabet-
ic retinopathy (PDR) [22].
Cell therapy has been proposed as a novel approach to
treat diabetic PDR. In this context, MSCs emerged as one
of the most promising candidates for several reasons. A
large body of evidence points out an equivalence between
MSCs and pericytes [23], making MSCs the ideal replace-
ment for the latter. Moreover, BM-derived MSCs have the
ability to partially differentiate into photoreceptors and ret-
inal pigmented epithelium in vitro and in vivo [24]. This
ability is important considered that neurodegenerative
events, including glial cell reactivity, microglial activation,
and neuronal apoptosis, take place at the early stage of
DR [25]. First phase I/II clinical trials using adult MSCs
have been carried out (https://www.clinicaltrials.gov,
NCT01068561 and NCT01560715) in re t in i t i s
pigmentosa. In the RETICELL clinical study, Siqueira
et al. demonstrated an improvement in patient quality of
life, unfortunately only for a short time, as any beneficial
effect had disappeared after 12 months [26]. Currently,
only two clinical trials with intravitreal injection of adult
MSCs in patients suffering from ischemic retinopathy and
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macular degeneration are ongoing (https://www.
clinicaltrials.gov, NCT01518842 and NCT01518127).
Besides MSCs, CD34+ HSCs represent a valid alternative.
In different animal models, intravitreally injected CD34+ cells
showed, similarly to MSCs, the ability to rescue retinal vas-
culature and a neuronal protective effect [27]. More impor-
tantly, intravitreal injection of BM-derived CD34+ cells is safe
and well tolerated on the long term [27]. Park et al. detected
CD34+ cells after 8 months from injections, with no histolog-
ical sign of intraocular tumor or abnormal tissue growth [28].
Those premises paved the way to the first clinical trial (https://
www.clinicaltrials.gov, NCT01736059) in patients who are
irreversibly blind from various retinal conditions, including
DR. In vivo imaging showed changes suggestive of new
cellular incorporation into the macula of the hereditary
macular degeneration study [29]. Previously, Siqueira et al.
treated patients with macular edema associated with macular
ischemia, observing an improvement in patient visual
performances [30].
Diabetic Cardiomyopathy
Diabetic cardiomyopathy (DCM) was firstly described in
1972 by Rubler et al. who observed congestive heart failure
in patients with no coronary artery disease (CAD) [31]. The
definition of DCM has evolved through the years and to date
comprises the presence of diabetic microangiopathy, myopa-
thy, and autonomic neuropathy. Briefly, DCM is characterized
by an increased left ventricular (LV) mass and wall thickness
frequently associated with cardiomyocyte hypertrophy [31].
Similar to other diabetic complications, DCM likely originates
from altered metabolism related to chronic hyperglycemia.
Insulin resistance leads to a switch from glucose oxidation
metabolism to free fatty acid oxidation which is more oxygen
demanding. Those events trigger cardiac ischemia inducing
the shift to anaerobic metabolism, which in turn produces
more lactate and acid metabolites resulting in lipid accumula-
tion and altered cardiomyocyte contraction and apoptosis
[32]. Increased oxidative stress and advanced glycation end
product (AGE) formation contribute to fibrosis and cell death,
while the occurrence of endothelial dysfunction manifests as
altered permeability and increased leukostasis, leading to
myocardial edema and inflammation [32].
Cell therapy is expected to benefit DCM through regener-
ative, pro-angiogenic, anti-fibrotic, and anti-inflammatory
mechanisms. MSCs showed the in vitro and in vivo ability
to differentiate into cardiomyocytes [33]. In the seminal work
by Nagaya et al., MSC therapy was able to significantly in-
crease capillary density and to decrease the collagen volume
fraction in the myocardium, resulting in decreased left ventric-
ular end-diastolic pressure [33]. The protective effect exerted
by MSCs is seemingly attributed to remarkable paracrine ac-
tivity. For instance, in vivo studies showed that intra-cardiac
injection ofMSCs in a rat model of post-ischemic heart failure
led to a significant decrease in ventricular fibrosis associated
with improved cardiac parameters. The effect was mainly me-
diated by the inhibition of MMP-9, a mediator of apoptosis in
DCM, and the promotion of MMP-2 activity, which inhibits
collagen deposition [34]. Additionally, MSCs protect
cardiomyocytes from apoptosis by upregulating 14-3-3 and
p-Ask1 proteins [35]. Moreover, MSCs are able to decrease
immune cell infiltration [36]. Cytokines and growth factors
could be used to potentiate stem cell mobilization and homing
to the myocardium. Improved mobilization with granulocyte
colony-stimulating factor (G-CSF) ameliorates the rat model
of CDM decreasing perivascular interstitial fibrosis [37]. Our
recent study in BM cells from infarcted patients demonstrated
that SDF-1 directedmigration enriches for cells with increased
healing activity [38]. Additionally, BM-derived EPCs not only
promote neovascularization but also exert anti-fibrotic action
in diabetic hearts by paracrine inhibition of miR-155 [39].
To date, BM cell therapy has been tested in several clinical
trials on patients with acute or chronic heart failure, producing
mixed results [40]. However, to the best of our knowledge, no
clinical trial has been so far conducted with BM cells for
treatment of DCM.
Diabetic Nephropathy
Diabetic nephropathy is the leading cause of end-stage renal
disease (ESRD) worldwide. Diabetic kidney disease is char-
acterized by glomerular hypertrophy, basement membrane
thickening, mesangial expansion, tubular atrophy, interstitial
fibrosis, and arteriolar thickening. Those morphological
changes are attributable to chronic hyperglycemia and en-
hanced oxidative stress. Podocyte dysfunction is key in these
pathological process.
BM cell therapy has been tested in animal models of dia-
betic nephropathy with promising results. In 2006, Lee et al.
reported that intracardial injection ofMSCs in a T1DMmouse
model improves metabolic control as well as glomerular mor-
phology, mesangial thickening, and macrophage infiltration
[41]. In a murine model of DM, Ezquer et al. obtained similar
results, even if no restoration of normal glucose levels was
observed. Interestingly, MSCs were detectable after 3 months
of injection [42]. In a rat model of diabetic nephropathy, im-
proved podocyte function was paralleled by decreased albu-
minuria [43]. Similar studies in a diabetic rat model provided
mechanistic insight of autologous MSC transplant. The reno-
protective mechanism of MSC therapy includes inhibition of
oxidative stress, possibly through improved insulin sensitivity
leading to better metabolic control [44]. Furthermore, rat bone
marrow-derived MSCs decrease macrophage infiltration by
downregulation of cytokines, like monocyte chemotactic pro-
tein 1 (MCP-1), interleukin 1β (IL-1β), interleukin 6 (IL-6),
and tumor necrosis factor α (TNF-α) [45]. Additionally,
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VEGF and anti-apoptotic protein B cell lymphoma 2 (bcl2)
are upregulated and transforming growth factor β (TGF-β)
and pro-apoptotic factor Bax are downregulated [46].
Inhibition in the TGF-β signaling pathway is associated with
decreased fibrosis, with this mechanism being likely mediated
by secreted protein osteogenic protein-1 (OP-1) [47]. A study
from Zhang et al. showed similar results in a db/db mouse
model injected with EPCs [48]. Finally, recruitment of healing
BM cells could occur in the beneficial effects of angiotensin
receptor antagonists in preventing diabetic glomerulosclerosis
[49].
Diabetic Neuropathy
Diabetic neuropathy (DNP) is a common and disabling man-
ifestation of DM and often overlaps with vascular complica-
tions. Sensory neuropathy is a typical form of peripheral neu-
ropathy characterized by an altered perception of noxious
stimuli. From a functional standpoint, it manifests as an in-
ability of neurons to produce proper amounts of neuropep-
tides, like substance P (SP) and calcitonin gene-related peptide
(CGRP), in response to tissue injury.
Pre-clinical cell therapy studies showed promising re-
sults for treatment of DNP. In a T1DM rat model,
MSCs ameliorated hypoalgesia and improved nerve con-
duction velocity, sciatic nerve blood flow, and capillary
number-to-muscle fiber ratio in soleus muscles [50].
MSCs showed the potential to support direct de novo
regeneration of neuronal cells [51]. However, paracrine
properties seem to be prevalent. Indeed, MSCs produce
a list of anti-inflammatory cytokines, which moderate
leukocyte recruitment, together with neurotrophic and
angiogenic factors such as nerve growth factor (NGF),
VEGF, and IGF-1 [52]. This dual action on nerves and
vessels is also exerted by EPCs. In a T1DM mouse
model, EPC administration increased VEGF, basic fibro-
blast growth factor (bFGF), and glioma-associated onco-
gene family zinc finger 1 (Gli 1) protein, which was
associated with increased proliferation of Schwann and
endothelial cells. Interestingly, engrafted EPCs tended to
co-localize near the vasa nervorum [53]. Differently
from other BM cell populations, freshly isolated BM-
derived mononuclear cells (MNCs) produced prevalent
improvements on nerves in a DNP rat model [54]. As
reported for other complications, in vivo data support
the possibility to explore endogenous cell mobilization
as a therapeutic alternative to classical cell therapy. In a
rodent model of DNP, intraperitoneal administration of
G-CSF improved nerve function, preventing axonal at-
rophy and demyelination, mainly due to peri-neuronal
recruitment of stem cells from BM. However, no fusion
with recipient cells or proof of BM cell differentiation
into neurons was observed, thus suggesting a paracrine
action by recruited cells [55].
Currently, no data from clinical trials are available regard-
ing BM cell therapy for treatment of DNP in patients.
Macrovascular Complications
Critical limb ischemia (CLI), the end stage of peripheral artery
disease (PAD), is caused by severe obstruction of blood flow
resulting in unbearable pain, ulcers, and a high risk for ampu-
tation. Surgical bypass or percutaneous revascularization, the
gold standard for the treatment of CLI, exerts only temporary
symptomatic alleviation. Furthermore, around one third of
patients with CLI cannot be revascularized because of
multivascular disease or occlusions of small-caliber blood
vessels [56]. Gene and cell therapies have been therefore pro-
posed as a possible complement or alternative to intervention-
al angioplasty.
Different pre-clinical and clinical trials have been carried
out in the recent years, mainly using BM-derived MNCs or
EPCs, with mixed results. A recent systematic review of clin-
ical trials with intramuscular delivery of BM-derived MNCs
in patients with CLI indicates that there is no evidence to
support this therapeutic approach. Only in one study was a
lower rate of amputation appreciated, pointing out that larger
randomized controlled trials are needed in order to provide
adequate statistical power [57]. On the other hand, another
systematic review identified 13 studies with proper controlled
groups using autologous transplantation of BM-derived stem
cells. Taken together, these studies suggest BM cells were well
tolerated and improved ischemic symptoms in patients with
DM, prolonging the amputation-free survival period and pro-
moting complete wound healing [58]. A recent double-blind,
randomized, placebo-controlled, phase I/II study showed
MSCs ameliorate the ankle brachial pressure index (ABPI)
and ankle pressure in patients with established CLI [59].
Conversely, autologous supplementation of CD133+ cells
through mobilization showed poor results due to senescence
of the stem cell compartment [60].
BM-derived stem cells have been also thoroughly investi-
gated in randomized clinical trials for stroke or acute myocar-
dial infarction (AMI) treatment. Despite differences on the
timing of cell transplantation after stroke onset, on the short-
or long-term follow-up, and on cell-culture conditions, all
studies have led to a significant functional improvement, with-
out adverse effects [61]. However, the limited number of par-
ticipants enrolled in those studies, associated with limited bio-
availability of BM stem cells in persons with DM, demands
further investigation to overcome these issues [61]. In AMI
treatment, the majority of clinical trials used BM MNCs [62,
63]. Gathered results demonstrated BM MNCs to be safe on
the long term, but modest hemodynamic improvements were
appreciated [63]. Additionally, MSCs have been used in
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clinical AMI trials. Although their use is safe, no definitive
results have been achieved yet [64].
The Downside: Evidence for Impairment
of BM-Derived Stem Cells Contributing to Diabetic
Complications
The BM is emerging as just one additional tissue stricken by
complications of DM. Initial data from pre-clinical and clini-
cal studies indicated DM causes quantitative and qualitative
impairments in circulating stem cells [65]. However, initial
damage directly occurs at the source-tissue level, before cells
are mobilized to the peripheral circulation, due to a remarkable
remodeling of all the components of the marrow niche [66••].
These changes lead to the disruption of stem cell homeostasis,
providing a further mechanism to explain and interpret periph-
eral complications.
Bone Marrow Microangiopathy
The BM is perfused by a complex network of vessels, formed
by penetrating arteries, distal arterioles, and sinusoidal capil-
laries. Sinusoidal capillaries form highly branched and irreg-
ular networks and are primarily found between hematopoietic
cells within the marrow cavity. Arteries contain comparably
few side branches and are mainly associated with bone-
forming cells, i.e., osteoblasts. Our seminal work provided
the first evidences that diabetic BM undergoes profound struc-
tural alterations [67]. Using a T1DMmouse model, we report-
ed a severe microvascular rarefaction responsible for marrow
hypoperfusion. Isolated endothelial cells from diabetic mice
presented higher levels of ROS production and upregulation
of the senescence marker β-galactosidase [67]. Endothelial
dysfunction was confirmed in a subsequent study showing
an increased vascular leakage of proteins and leukocytes, both
hallmarks of vascular diabetic complications. This was asso-
ciated with an increased activity of redox-sensitive RhoA
GTPase and downstream kinase ROCK 1/2. Both RhoA si-
lencing with a dominant negative form and ROCK inhibition
rescued endothelial dysfunction, restoring Akt-dependent pro-
duction of angiocrine factors, and vascular permeability [68•].
DM also affected the stem cell compartment as HSCs were
mostly depleted in the extended, low-perfused part of the mar-
row [67]. Those findings were confirmed in a T2DM mouse
model [69], as well as in people with T2DM [66••].
Histopathological measurements of human BM documented
microvascular rarefaction at the sinusoid and arteriole levels,
osteopenia, and increased adipogenesis [66••]. Molecular
studies highlighted the downregulation of miRNA-155, a
master regulator of HSC self-renewal, to be a key underpin-
ning mechanism of diabetic CD34+ cell pauperization [66••].
The occurrence of remodeling of source tissuemay represent a
serious obstacle to efficient harvesting or mobilization in view
of autologous transplantation of CD34+ cells. In fact, a recent
study in participants with refractory angina has shown that the
efficacy of this treatment is clearly dose dependent [70]. This
concept is strengthened by the observation of a delayed
repopulating capacity of diabetic BM CD34+ cells [71].
BM Neuropathy and Mobilopathy
Another master regulator of stem cell homeostasis and traf-
ficking is represented by the BM sensorial and autonomic
innervation. HSC release into the bloodstream is regulated
by a circadian cycle through the activity of noradrenergic fi-
bers [72]. Sympathetic and nociceptive fibers stimulate stem
cell release either directly or indirectly through modulation of
stromal cells, i.e., perivascular cells and osteoblasts [73].
Katayama et al. recently showed that HSC mobilization by
G-CSF was reduced in sympathectomized mice [74]. They
also showed that G-CSF attenuates osteoblast function, via
the sympathetic nervous system, thereby facilitating HSC de-
tachment from the endosteal niche. In addition, human
CD34+ cells express β2-adrenergic and nociceptive receptors
that are upregulated by G-CSF [75]. These studies demon-
strate that neurotransmitters serve as direct chemoattractants
to HSCs under conditions where the mobilization of regener-
ative cells is required to promote healing of injured or ische-
mic peripheral tissues [71]. In fact, abrogation of nociceptive
signaling by genetic or pharmacological manipulation results
in delayed recovery from ischemia [73]. Likewise, the occur-
rence of autonomic neuropathy accounts for the known defec-
tive mobilization of HSCs in persons with DM [76, 77]. A
clinical trial (https://www.clinicaltrials.gov, NCT01102699)
demonstrated that participants with DM challenged with G-
CSF have a reduced mobilization of HSCs, due to altered
expression of dipeptidyl peptidase-4 (DPP4, also known as
adenosine deaminase complexing protein 2 or CD26) [78,
79]. DPP-4’s natural substrate is the chemokine SDF-1α, a
major regulator of the stem/progenitor cell trafficking between
the BM and circulation. A meta-analysis review on clinical
trials pointed out that G-CSF is the main affected mobilization
signaling pathway in people with DM [80]. Several studies in
animal models replicated the human findings and provided an
insight for the underlying mechanisms [81]. In particular,
Albiero et al. demonstrated that both experimental murine
models of T1DM and T2DM develop BM autonomic neurop-
athy with an impaired mobilization of HSCs. This effect is
mediated by upregulation of p66Shc and downregulation of
Sirtuin 1 (Sirt1), together leading to elevated expression of the
adhesion molecule CD62L (L-selectin). Knock-out of
p66Shc, as well as overexpression of Sirt1, was able to restore
proper stem cell trafficking [82•]. In our recent study, we dem-
onstrated a rarefaction in nociceptive fibers in the BM of pa-
tients with T2DM [83••]. This was associated with a drastic
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reduction of NK1R, the receptor for nociceptive transmitter
SP [83••]. In addition, following induction of limb ischemia,
diabetic mice showed an incapacity to create a peripheral-to-
BM SP gradient. As said before, this gradient drives the mo-
bilization and homing of HSCs to the ischemic site [73].
Consequently, there was a reduction in the recruitment of
NK1R+ HSCs to the ischemic limb muscles of diabetic mice,
resulting in delayed recovery and depressed reparative angio-
genesis [83••]. Collectively, these reports indicate that neurop-
athy conjointly with microangiopathy may adversely affect
stem cell-based therapies in patients with DM.
Adipogenesis and Bone Resorption
Along with microangiopathy and autonomic neuropathy, in-
creased adipose tissue is a hallmark of BM remodeling in DM,
both in animal models and humans [66••, 67]. These changes
are likely due to enhanced adipogenesis fromMSCs [84]. This
is associated both in humans and animal models with a de-
crease of the ratio between trabecular bone mass and adipose
tissue [66••, 67]. Increased deposition of adipose tissue, as
well as a reduction in the number of osteoblasts, could be
enlisted among the causes of stem cell pauperization observed
in diabetic BM. In fact, adipocytes can disturb the cellular
network inside the niches by releasing oxidative and inflam-
matory mediators [85], activating the AGE pathway [86], and
modifying the metabolic milieu [87].
BM-Derived Stem Cells Involved in Other Complications
In previous sections, we have illustrated how DM complica-
tions extend to the BM and impact on stem cells and their
niche. The movement of damaged cells along with a spectrum
of lineage-committed cells into the circulation may pave the
way for the enhancement of peripheral complications. This
assumption is supported by new experimental evidence show-
ing that BM-derived cells can actively participate at the two
different stages of DR. In the non-proliferative stage, BM-
derived CD11b-positive cells contribute to capillary degener-
ation through leukostasis [88]. As demonstrated by Li et al.,
BM-mobilized monocytes can contribute to the generation of
oxidative stress and vessel regression [89]. On the other hand,
BM-derived EPCs play a pivotal role in the angiogenic stage
of DR via the secretion of growth factors and chemokines
[90]. Studies investigating the correlation of EPC numbers
and their contribution to DR in humans produced mixed re-
sults. For instance, CD34+ cells were found either increased,
decreased, or unchanged in T2DM-associated DR [91, 92],
whereas in T1DM, EPC numbers correlate well with the pro-
liferative grade of the disease [93, 94]. With regard to diabetic
nephropathy, clinical studies pointed out a correlation between
microalbuminuria and circulating CD34+ cells [95, 96]. Only
pre-clinical data are available regarding diabetic neuropathy.
In an elegant study using a T1DM animal model, Terashima
et al. showed that BM cells are indeed involved in the patho-
biology of diabetic neuropathy, being able to fuse with neu-
rons in the dorsal root ganglia [97]. In a following study, they
found similar results in diabetic animals, demonstrating these
fusion events occur between neuronal cells and a specific sub-
set of HSCs expressing insulin and TNF-α [98•]. The link
between BM pathology and vasculopathy seemingly involves
the spleen as a mandatory site of cell commitment to an in-
flammatory phenotype. It is well known that patients with
acute coronary syndromes have a high risk of recurrent events.
This was ascribed to mobilization of myeloid cells that have
disruptive activity of atherosclerotic plaques. These hemato-
poietic stem and progenitor cells are liberated fromBMniches
via sympathetic nervous system signaling. They then colonize
the spleen, yielding a sustained boost in monocyte production
[99].
Restore BM Functionality to Improve Cell Therapy
of Diabetic Complications
Data reported in previous sections suggest that DM poses
serious challenges to current stem cell therapies. The obvious
approach to interrupt the vicious cycle between peripheral and
BM damage is to reinforce classical interventions for achieve-
ment of proper and consistent metabolic control (Fig. 1).Well-
designed clinical trials similar to the UK Prospective Diabetes
Study should be performed to establish the association be-
tween stable normalization of hyperglycemia and improve-
ment of BM pathology. Performing such a study will be com-
plicated by the need of an invasive procedure to collect BM
material. Alternatively, analyses of circulating cells could be
used as a surrogate endpoint. The use of ROS scavengers
could also provide opportunities. Studies in experimental
models indicate that abrogation of p66Shc results in protection
from angiotensin II-induced cardiac damage [100], improve-
ment of reparative angiogenesis and reduction of myocyte
apoptosis following induction of limb ischemia, and preserva-
tion of satellite cell proliferation and differentiation under
in vitro conditions of high oxidative stress [101, 102].
Blockade of this pathway by specific inhibitors of protein
kinase C β (PKCβ), the enzyme responsible for p66Shc phos-
phorylation/activation, was demonstrated to ameliorate the
vascular dysfunction in diabetic animals, providing a new
strategy for the treatment of diabetic vascular complications
[103, 104]. Indeed, the PKCβ inhibitor LY333531, also
known as ruboxistaurin, is under advanced investigation in
clinical trials to treat DR. It would be interesting to investigate
if PKCβ inhibitors are useful in preventing or rescuing BM
stem cell availability and functionality in DM.
Thiamine pyrophosphate is the cofactor for transketolase,
the rate-limiting enzyme that shunts glyceraldehyde 3-
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phosphate and fructose 6-phosphate from glycolysis into the
non-oxidative branch of the pentose phosphate pathway.
Thiamine deficiency has been reported in diabetes, and cor-
rection of the defect by supplementation of thiamine or its
derivative, benfotiamine, was shown to protect against diabet-
ic nephropathy and retinal microangiopathy [105]. We have
also shown that benfotiamine supplementation prevented mi-
croangiopathy and hypoperfusion of diabetic BM.
Furthermore, benfotiamine reduced oxidative stress and oxi-
dative damage of DNA in BM cells. Importantly, these effects
were associated with prevention of HSC depletion, both in
terms of absolute number and relative proportion to total
BM cells, and inhibition of apoptosis [67]. Clinical studies
using benfotiamine are therefore eagerly waited. Moreover,
similar strategies could be useful to counteract neuropathy
and related insensitivity to chemokine stimulation, e.g.,
mobilopathy [82•].
Mobilopathy could also benefit by the use of alternative
cytokines different from G-CSF. In a retrospective study,
Fadini et al. observed that inability of G-CSF to mobilize stem
cells in patients with DM was abrogated when administrated
in conjunction with pleraxifor, an antagonist of the SDF-1/
CXCR4 axis [106•]. Moreover, our study on nociceptive sig-
naling paves the way for the application of modulators of pain
as a novel strategy to help proper mobilization [83••].
Alternatively, specific treatment on ex vivo isolated cells
could help to restore their full regenerative potential. As
discussed earlier, BM-derived cells can be isolated and ex-
panded ex vivo for autologous or allogeneic transplantation.
Gene therapy could be a viable approach in order to rescue
stem cell functionality. For instance, the microRNA-155
downregulation inHSCs represents a candidate target tomain-
tain the pool of original stem cells in diabetic BM [66••].
Conversely, silencing of microRNA-15a and microRNA-16
could ameliorate EPC angiogenic potential [107]. A less prob-
lematic approach would be the pre-conditioning of BM-
derived stem cells in order to improve their regenerative po-
tential [108]. Pre-conditioning with anoxic microenvironment
increased the cardio-protective properties of MSCs in a model
of diabetic cardiomyopathy [109]. Supplementing the culture
media with a cocktail of potentiating cytokines could also be a
viable option [110, 111]. However, it has to be taken into
account that transplanted stem cells, either fortified autolo-
gous cells or healthy allogeneic cells, have to face a diabetic
milieu which can obliterate any salutary improvement.
Conclusions
In summary, BM cell therapy represents a potential opportu-
nity for treatment of diabetic complications, yet its potential is
not fully explored and realized. Even in the case in which this
regenerative approach will prove to be marginally useful in a
clinical setting, the concept of restoring the proper BM envi-
ronment remains of vital importance and requires attention for
tailoring novel therapies capable of restating global organ ho-
meostasis in patients with DM.
Fig. 1 Mechanisms responsible
for bone marrow remodeling
under chronic hyperglycemia and
oxidative stress and potential
therapeutic applications. The
orange box represents early
pathobiological events which
trigger later ones, shown in the
yellow boxes. Possible therapeutic
applications are shown in the
green boxes
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